Shirt a Phobia

Sample Page

Landipirdine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RO-5025181 and SYN-120) is a serotonin 5-HT2A and 5-HT6 receptor antagonist which was under development for the treatment of dementia and cognition disorders but was never marketed.[1][2][3] It is taken orally.[1] The drug was developed by Roche, Accorda Therapeutics, and Biotie Therapies.[1] It reached phase 2 clinical trials for dementia and phase 1 trials for cognition disorders prior to the discontinuation of its development in 2020.[1][2] Landipirdine was first described in the scientific literature by at least 2010.[4][5]

References

  1. ^ a b c d “Acorda Therapeutics”. AdisInsight. 9 March 2020. Retrieved 18 January 2026.
  2. ^ a b Wicke K, Haupt A, Bespalov A (2015). “Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease”. Expert Opinion on Investigational Drugs. 24 (12): 1515–1528. doi:10.1517/13543784.2015.1102884. PMID 26548316.
  3. ^ Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, et al. (September 2023). “Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial”. Parkinsonism & Related Disorders. 114 105511. doi:10.1016/j.parkreldis.2023.105511. PMID 37532622.
  4. ^ Ivachtchenko AV, Ivanenkov YA, Tkachenko SE (September 2010). “5-hydroxytryptamine subtype 6 receptor modulators: a patent survey”. Expert Opinion on Therapeutic Patents. 20 (9): 1171–1196. doi:10.1517/13543776.2010.494661. PMID 20716023.
  5. ^ Rossé G, Schaffhauser H (2010). “5-HT6 receptor antagonists as potential therapeutics for cognitive impairment”. Current Topics in Medicinal Chemistry. 10 (2): 207–221. doi:10.2174/156802610790411036. PMID 20166958.